{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:00:36Z","timestamp":1778644836859,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"NIH\/NCI","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02152-0","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:54:16Z","timestamp":1769878456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sequential use of PI3K\/AKT\/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Sherry","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmitti","family":"Teysir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Safonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Bromberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehnaj","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedram","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"2152_CR1","doi-asserted-by":"crossref","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.","DOI":"10.1093\/jnci\/dju055"},{"issue":"1","key":"2152_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge","year":"2020","unstructured":"Sledge GW, Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone Receptor\u2013Positive, ERBB2-Negative breast cancer that progressed on endocrine Therapy\u2014MONARCH 2: A randomized clinical trial. JAMA Oncol. 2020;6(1):116\u201324.","journal-title":"JAMA Oncol"},{"issue":"6","key":"2152_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Mart\u00edn M, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514\u201324.","journal-title":"N Engl J Med"},{"issue":"7418","key":"2152_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Comprehensive molecular portraits","year":"2012","unstructured":"Comprehensive molecular portraits. Of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"key":"2152_CR5","doi-asserted-by":"publisher","first-page":"11479","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479.","journal-title":"Nat Commun"},{"issue":"6","key":"2152_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139.","journal-title":"N Engl J Med"},{"issue":"20","key":"2152_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al. Alpelisib for PIK3CA-Mutated, hormone Receptor-Positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340.","journal-title":"N Engl J Med"},{"issue":"22","key":"2152_CR8","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, et al. Capivasertib in hormone Receptor-Positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370.","journal-title":"N Engl J Med"},{"key":"2152_CR9","doi-asserted-by":"crossref","unstructured":"Chia S, Neven P, Ciruelos EM, Lerebours F, Ruiz-Borrego M, Drullinsky P, Prat A,Park YH, Juric D, Turner NC et al. Alpelisib\u2009+\u2009endocrine therapy in patients with <\u2009i\u2009>\u2009PIK3CA-mutated, hormone receptor\u2013positive,human epidermal growth factor receptor 2\u2013negative, advanced breast cancer: analysis of all 3 cohorts of the BYLieve study. J Clin Oncol 2023;41(16_suppl):1078\u20131078.","DOI":"10.1200\/JCO.2023.41.16_suppl.1078"},{"issue":"12","key":"2152_CR10","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25(12):e629\u201338.","journal-title":"Lancet Oncol"},{"issue":"17","key":"2152_CR11","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Sunpaweravong P, Musolino A, et al. Inavolisib-Based therapy in PIK3CA-Mutated advanced breast cancer. N Engl J Med. 2024;391(17):1584\u201396.","journal-title":"N Engl J Med"},{"key":"2152_CR12","doi-asserted-by":"publisher","first-page":"S382","DOI":"10.1016\/j.annonc.2020.08.439","volume":"31","author":"F Nichetti","year":"2020","unstructured":"Nichetti F, Marra A, Giorgi CA, Randon G, Scagnoli S, De Angelis C, Molinelli C, Ferraro E, Trapani D, Milani A, et al. 337P efficacy of everolimus plus exemestane in CDK 4\/6 inhibitors-pretreated or na\u00efve HR-positive\/HER2-negative breast cancer patients: a secondary analysis of the EVERMET study. Ann Oncol. 2020;31:S382.","journal-title":"Ann Oncol"},{"issue":"2","key":"2152_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/onco.13609","volume":"26","author":"MM Cook","year":"2021","unstructured":"Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI. Everolimus plus exemestane treatment in patients with metastatic hormone Receptor-Positive breast cancer previously treated with CDK4\/6 inhibitor therapy. Oncologist. 2021;26(2):101\u20136.","journal-title":"Oncologist"},{"issue":"16","key":"2152_CR14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41388-024-02986-6","volume":"43","author":"A Vasseur","year":"2024","unstructured":"Vasseur A, Cabel L, Hego C, Takka W, Trabelsi Grati O, Renouf B, Lerebours F, Loirat D, Brain E, Cottu P, et al. Fulvestrant and everolimus efficacy after CDK4\/6 inhibitor: a prospective study with Circulating tumor DNA analysis. Oncogene. 2024;43(16):1214\u201322.","journal-title":"Oncogene"},{"issue":"12","key":"2152_CR15","doi-asserted-by":"publisher","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","volume":"25","author":"HS Rugo","year":"2024","unstructured":"Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, et al. Alpelisib plus fulvestrant in <\u2009em\u2009>\u2009PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25(12):e629\u201338.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2152_CR16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","volume":"2","author":"S Chandarlapaty","year":"2016","unstructured":"Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, et al. Prevalence of ESR1 mutations in Cell-Free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. 2016;2(10):1310\u20135.","journal-title":"JAMA Oncol"},{"key":"2152_CR17","doi-asserted-by":"crossref","unstructured":"Juric D, Rugo HS, Reising A, Ma C, Ciruelos EM, Loibl S, Singer CF, Sohn J, Campone M, Conte P et al. Alpelisib (ALP)\u2009+\u2009fulvestrant (FUL) in patients (pts) with hormone receptor\u2013positive (HR+), human epidermal growth factor receptor 2\u2013negative (HER2\u2013) advanced breast cancer (ABC): biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study. J Clin Oncol. 2022;40(16_suppl):1006\u20131006.","DOI":"10.1200\/JCO.2022.40.16_suppl.1006"},{"key":"2152_CR18","doi-asserted-by":"publisher","first-page":"103334","DOI":"10.1016\/j.critrevonc.2021.103334","volume":"162","author":"SR Vitale","year":"2021","unstructured":"Vitale SR, Martorana F, Stella S, Motta G, Inzerilli N, Massimino M, Tirr\u00f2 E, Manzella L, Vigneri P. PI3K Inhibition in breast cancer: identifying and overcoming different flavors of resistance. Crit Rev Oncol Hematol. 2021;162:103334.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2152_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s42003-022-03296-x","volume":"5","author":"G Bianco","year":"2022","unstructured":"Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, Konantz M, Srivatsa S, Montazeri H, Panebianco F, et al. GATA3 and MDM2 are synthetic lethal in Estrogen receptor-positive breast cancers. Commun Biology. 2022;5(1):373.","journal-title":"Commun Biology"},{"issue":"5","key":"2152_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-14-1042","volume":"5","author":"S Werner","year":"2015","unstructured":"Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, et al. Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid\u2013Induced 2. Cancer Discov. 2015;5(5):506\u201319.","journal-title":"Cancer Discov"},{"issue":"10","key":"2152_CR21","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3390\/genes13101763","volume":"13","author":"A Raphael","year":"2022","unstructured":"Raphael A, Salmon-Divon M, Epstein J, Zahavi T, Sonnenblick A, Shachar SS. Alpelisib efficacy in hormone Receptor-Positive HER2-Negative PIK3CA-Mutant advanced breast cancer Post-Everolimus treatment. Genes. 2022;13(10):1763.","journal-title":"Genes"},{"issue":"8","key":"2152_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/sj.bjc.6603353","volume":"95","author":"RT Kurmasheva","year":"2006","unstructured":"Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer. 2006;95(8):955\u201360.","journal-title":"Br J Cancer"},{"issue":"1","key":"2152_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol. 2011;6(1):17\u201327.","journal-title":"Target Oncol"},{"issue":"1","key":"2152_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2007-03-080796","volume":"111","author":"J Tamburini","year":"2008","unstructured":"Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, et al. Mammalian target of Rapamycin (mTOR) Inhibition activates phosphatidylinositol 3-kinase\/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic Inhibition of both pathways. Blood. 2008;111(1):379\u201382.","journal-title":"Blood"},{"issue":"5712","key":"2152_CR25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098\u2013101.","journal-title":"Science"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02152-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02152-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:01:55Z","timestamp":1772794915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-025-02152-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2152"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02152-0","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}